Idiopathic Pulmonary Fibrosis

Recombinant human pentraxin 2 slows the decline in lung function in idiopathic pulmonary fibrosis

June 07, 2018

The use of recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis.

Treatment for Idiopathic Pulmonary Fibrosis Gets Orphan Drug Designation

By April 10, 2018

RP5063 is a new chemical entity with a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways.

Sirolimus May Be Beneficial in DIPNECH Syndrome

April 10, 2018

The patients began treatment with oral sirolimus; after 1 year of treatment, there was improvement in exertional dyspnea in all 3 patients.

Cluster of Idiopathic Pulmonary Fibrosis Cases ID'd Among Dentists

By March 14, 2018

Some substances used while conducting these tasks contained silica, polyvinyl siloxane, alginate, and other compounds with known or potential respiratory toxicity.